AstraZeneca has sold their right to sell Zoladex (generic of Goserelin) in the United States and Canada to TerSera Therapeutics LLC, headquartered at Illinois, USA. And the main reason for this big move is because AstraZeneca is keen to focus more on newer Oncology products. The deal is expected to be finalized by the end of March 2017, and it will see AstraZeneca receive an upfront payment of $250 million for foregoing of their rights to sell Zoladex in the United States and in Canada. The deal also provides with AstraZeneca with double-digit ongoing payments based on Quarterly Sales and there also includes a clause of AstraZeneca receiving additional $70million, if Zoladex (Generic of Goserelin) meets the series of desired sales milestones
